Efifcacy and Prognostic Factors of Alpha-fetoprotein Negative Hepatocellular Carcinoma by Transcatheter Arterial Chemoembolization / 中国医学影像学杂志

ABSTRACT

Purpose To assess the efficacy and prognostic factors of alpha-fetoprotein (AFP) negative hepatocellular carcinoma (HCC) by transcatheter arterial chemoembolization (TACE). Materials and Methods 67 AFP negative HCC patients and 67 AFP positive HCC patients underwent TACE, the survival of two groups was compared, and the prognostic factors were also analyzed. Results All 134 HCC patients were followed up for 24 months, the one-year, two-year and five-year survival rate of AFP negative and AFP positive HCC patients were 86.6%, 58.2%, 31.3%; and 81.6%, 37.8%, 13.4%, respectively, with median survival time of 34.0 months and 19.0 months, respectively. The survival rate were statistically different between AFP negative and AFP positive HCC patients (P400 ng/ml and AFP ≤400 ng/ml were 18.0 months and 31.0 months, respectively with statistical difference (P<0.05). Univariate analysis showed that Child-Pugh classification, histological grade, tumor size, tumor number, portal vein tumor thrombus, BCLC staging and AFP level were independent risk factors influencing the prognosis of HCC patients. Conclusion AFP negative and AFP positive (AFP ≤400 ng/ml) HCC patients achieves good efficacy and prognosis by TACE, Child-Pugh classification, portal vein tumor thrombus, BCLC staging and AFP level were risk factors influencing the prognosis of HCC patients.